Novo Nordisk Already Plans A 'Next Generation' Oral Semaglutide - CEO
Planned next generation of oral semaglutide 'is in the early research stage', Lars Fruergaard Jorgensen tells Scrip.
You may also be interested in...
Celgene makes play into RNA-expression correction via neuroscience partnership and equity investment with Skyhawk. Novartis’ Sandoz agreed to commercialize Adamis’ Symjepi, a competitor to EpiPen, in the US.
In second Phase III diabetes study to report, oral GLP-1 agonist semaglutide misses some weight loss goals when compared with Boehringer/Lilly's SGLT-2 inhibitor Jardiance.
Just moving into Phase II with a pair of candidates, Pfizer trails smaller rivals in the NASH race, but the deep-pocked firm may have the assets to develop its own proprietary combination therapy for the large-scale unmet medical need.